Ethoss® Regeneration Ltd has further expanded its international reach in the multi-billion-pound dental market after signing a series of new distribution deals across Western Europe.
Following the launch of ethoss® in 2015, the company has achieved rapid growth in the UK and internationally – with deals signed with partners in Ireland, Italy, Netherlands, Belgium and France in recent weeks.
ethoss® is a synthetic bone graft material used to help patients regenerate bone to support dental implants.
Unlike many other products on the market, ethoss® is completely free from any animal or human content and works extremely quickly – generating 50 per cent new bone for the patient after just 12 weeks. This means surgical procedures can be completely more quickly and reliably, benefitting both patient and dentist.
Due to its innovative design, ethoss® doesn’t require an expensive separate collagen membrane to be used in the procedure. As well as reducing the overall cost to both dentist and patient, this helps to speed up healing times significantly.
The uniqueness of the product has meant the company has already established a foothold in the German and Greek markets and is seeing significant growth in both countries.
Many of the new international relationships have come as a result of a successful exhibition at the IDS trade fair in Cologne, Germany – the biggest dental exhibition in the world – at which ethoss® exhibited on the UK Pavilion with assistance and funding from the government’s Department for International Trade.
Paul Harrison, Managing Director of ethoss® Regeneration, said: “As a company we are enjoying extraordinary levels of growth, which has been in large part due to our comprehensive export strategy.
“Whilst we have established significant market share in the UK, the country only accounts for around 2 per cent of the total European market for dental grafting products, so expanding our international profile certainly provides us with some really interesting opportunities.
“Europe is a natural first choice for us as medical device regulation is harmonised across the EU, meaning we can quickly launch without having to seek separate approvals.
“The feedback we continue to receive for ethoss® – both anecdotally and clinically – gives us the confidence that it can make a genuine difference to both patients and clinicians across the world.
“We are very still relatively young as a company but we are excited to be taking this technology overseas and it is particularly encouraging to see growth in more established markets such as those in Western Europe.”
For more information on ethoss contact +44 (0) 1535 843 106 or email firstname.lastname@example.org.